Skip to content
Menu

Leerink Partners Initiates Coverage On Palvella Therapeutics with Outperform Rating, Announces Price Target of $228

Benzinga Newsdesk 4 hours ago

Analyst RatingsNewsInitiationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Leerink Partners analyst Jenny Gonzalez-Armenta initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating and announces Price Target of $228.

Leerink Partners analyst Jenny Gonzalez-Armenta initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating and announces Price Target of $228.

Read at benzinga.com